Apurinic endonuclease activity in adult gliomas and time to tumor progression after alkylating agent-based chemotherapy and after radiotherapy

Clinical Cancer Research

Volumn 10, Issue 23, 2004, Pages 7875-7883

  Bobola, Michael S ^a,c   Emond, Mary J ^b   Blank, A ^b   Meade, Elizabeth H ^a   Kolstoe, Douglas D ^a   Berger, Mitchel S ^d   Rostomily, Robert C ^a   Silbergeld, Daniel L ^a   Spence, Alexander M ^a,b   Silber, John R ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CARMUSTINE; CISPLATIN; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; ENDONUCLEASE; FLUOROURACIL; HYDROXYUREA; LOMUSTINE; MITOLACTOL; PROCARBAZINE; TEMOZOLOMIDE; TIOGUANINE; VINCRISTINE;

ADULT; ADULT DISEASE; AGE; APURINIC SITE; APYRIMIDINIC SITE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; DISEASE ASSOCIATION; DNA CLEAVAGE; DNA REPAIR; DRUG RESISTANCE; ENZYME ACTIVITY; FEMALE; GENDER; GLIOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; PREDICTION; PRIORITY JOURNAL; RADIOSENSITIVITY; TUMOR GROWTH;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTOMA; BRAIN NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; NEOPLASM STAGING; OLIGODENDROGLIOMA; RADIATION TOLERANCE; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 9744268998     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1161     Document Type: Article

References (56)

1. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-oncol 2002;4:278-99.
2. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumours in adults. Lancet 2003;361:323-31.
3. Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61:215-25.
4. Walker DG, Kaye AH. Low grade glial neoplasms. J Clin Neurosci 2003;10:1-13.
5. Walker MD, Alexander E Jr, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978;49:333-43.
6. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res 2000;6:2585-97.
7. Stupp R, Dietrich PY, Ostermann S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-82.
8. Levin VA, Edwards MS, Wright DC, et al. Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 1980;64: 237-44.
9. Levin VA, Prados MD. Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol 1990;10:766-71.
10. Rostomily RC, Spence AM, Duong D, McCormick K, Bland M, Berger MS. Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 1994;35:378-8.
11. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002;359:1011-8.
12. van den Bent M, Chinot OL, Cairncross JG. Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro-oncol 2003;5:128-38.
13. Wara WM, Sheline GE. Radiation therapy of malignant brain tumors. Clin Neurosurg 1978;25:397-402.
14. Shapiro WR, Shapiro JR. Biology and treatment of malignant glioma. Oncology 1998;12:233-40.
15. Bauman G, Pahapill P, Macdonald D, Fisher B, Leighton C, Cairncross G. Low grade glioma: measuring radiographic response to radiotherapy. Can J Neurol Sci 1999;26:18-22.
16. Kortmann RD. Radiotherapy in low-grade gliomas: pros. Semi Oncol 2003;30(Suppl 19):29-33.
17. Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg 1993;78:909-14.
18. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003;21:646-51.
19. 6-alkylguanine by alkyltransferases. Mutat Res 2000;462:83-100.
20. 6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin. Clin Cancer Res 1996;2:735-41.
21. 6- benzyl-2′-deoxyguanosine and 1,3-bis(2-chloroethyl)1-nitrosourea. Clin Cancer Res 1999;5:3676-81.
22. Belanich M. Pastor M, Randall T, et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996;56:783-8.
23. 6-methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chlorethylriitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998;10:3310-5.
24. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-4.
25. 6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: Frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Caner Res 1999;5:807-14.
26. Evans AR, Limp-Foster M, Kelley MR. Going APE over ref-1. Mutat Res 2000;461:83-108.
27. Silber JR, Bobola MS, Blank A, et al. The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clin Cancer Res 2002;8:3008-38.
28. Demple B, Harrison L. Repair of oxidative damage to DNA: Enzymology and biology. Annu Rev Biochem 1994;63:915-48.
29. Bobola MS, Blank A, Berger MS, Stevens BA, Silber JR. Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin Cancer Res 2001;7:3510-18.
30. 6-methylguanine-DNA methyltransferase activity in adult gliomas: Relation to patient and tumor characteristics. Cancer Res 1998;58: 1068-73.
31. Chen D, Herman V, Demple B. Two distinct human diesterases that act on 3′-fragments of deoxyribose in radical damaged DNA. Nucleic Acids Res 1991;19:5907-14.
32. Diete S, Treuheit T, Dietzmann K, Schmidt U, Wallesch CW. Sex differences in length of survival with malignant astrocytoma, but not with glioblastoma. J Neurooncol 2001;53:47-9.
33. Kunwar S, Mohapatra G, Bollen A, Lamborn KR, Prados M, Feuerstein BG. Genetic subgroups of anaplastic astrocytomas correlate with patient age and survival. Cancer Res 2001;61:7683-8.
34. Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol 2003;30:(Suppl 19):10-4.
35. Keles GE, Lamborn K, Chang SM, Prados MD, Berger, MS. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy J Neurosurg 2004;100:41-6.
36. Ludlum DB. The chloroethylnitrosoureas: sensitivity and resistance to cancer chemotherapy at the molecular level. Cancer Investig 1997; 15:588-98.
37. Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, preclinical development and clinical trials. Cancer Treat Rev 1997;23: 35-61.
38. Krokan HE, Nilsen H, Skorpen F, Otterlei M, Slupphug G. Base excision repair of DNA in mammalian cells. FEBS Lett 2000;476:73-7.
39. Lhomme J, Constant J-F, and Demeunyck M. Abasic DNA structure, reactivity and recognition. Biopolymers 1999;52:65-83.
40. Mitra S, Izumi T, Boldogh I, Bhakat KK, Hill JW, Hazra TK. Choreography of oxidative damage repair in mammalian genomes. Free Radic Biol Med 2002;33:15-28.
41. Loeb LA, Preston BD. Mutagenesis by apurinic/apyrimidinic sites. Ann Rev Genet 1986;20:201-30.
42. Sutton MD, Walker GC. Managing DNA polymerases: coordinating DNA replication, DNA repair, and DNA recombination. Proc Natl Acad Sci USA 2001;98:8342-9.
43. Higuchi K, Katayama T, Iwai S, Hidaka M, Horiuchi T, Maki H. Fate of DNA replication fork encountering a single DNA lesion during oriC plasmid DNA replication in vitro. Genes Cells 2003;8: 437-49.
44. Ono Y, Furuta T, Ohmoto T, Akiyama K, Seki S. Stable expression in rat glioma cells of sense and antisense nucleic acids to a human multifunctional enzyme, APEX nuclease. Mutat Res 1994; 315:55-63.
45. Roth TJ, Xu Y, Luo M, Kelley MR. Human-yeast chimeric repair protein protects mammalian cells against alkylating agents: enhancement of MGMT protection. Cancer Gene Ther 2003;10:603-10.
46. Gaiddon KZ, Xu Q, Holbrook NJ. Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo. EMBO J 1999;18: 5609-21.
47. Nozaki M, Tada M, Kobayashi H, et al. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. Neuro-oncol 1999;1:124-37.
48. Kakolyris S, Giatromanolaki A, Koukourakis K, et al. Nuclear localization of human AP endonuclease 1 (HAP1/Ref-1) associates with prognosis in early operable non-small cell lung cancer (NSCLC). J Pathol 1999;189:351-7.
49. Puglisi F, Aprile G, Minisini AM, et al. Prognostic significance of Apea/ref-1 subcellular localization in non-small cell lung carcinomas. Anticancer Res 2001;21:4041-9.
50. Koukourakis MI, Giatromanolaki A, Kakolyris S, et al. Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/ Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome. Int J Radiat Oncol Biol Phys 2001;50:27-36.
51. Puglisi F, Barbone F, Tell G, et al. Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas. Oncol Rep 2002;9:11-7.
52. Fishel ML, Seo YR, Smith ML, Kelley MR. Imbalancing the DNA base excision repair pathway in the mitochondria; targeting and over-expressing N-methylpurine DNA glycosylase in mitochondria leads to enhanced cell killing. Cancer Res 2003;63:608-15.
53. Stuart JA, Hashiguchi K, Wilson DM 3rd, Copeland WC, Souza-Pinto NC, Bohr VA. DNA base excision repair activities and pathway function in mitochondrial and cellular lysates from cells lacking mitochondrial DNA. Nucleic Acids Res 2004;32:2181-92.
54. Burton EC, Lamborn KR, Feuerstein BG, et al. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res 2002; 62:6205-10.
55. Mendez F, Goldman JD, Bases RE. Abasic sites in DNA of HeLa cells induced by lucanthone. Cancer Investig 2002;20:983-91.
56. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2000;18:3522-8.